Vollmer NJ, Rivera CG, Stevens RW, et al. - Researchers sought to determine the incidence of adverse events (ADE) resulting in unplanned drug discontinuation when fluoroquinolones (FQs) are used for periprosthetic joint infections (PJI). Of 156 included patients treated for staphylococcal PJI with debridement, antibiotics, and implant retention (DAIR), 64 had total hip arthroplasty (THA) and 92 had total knee arthroplasty (TKA) infections. Overall, 35.6% of patients in the FQ group and 3% of patients in the non-FQ group had unplanned drug discontinuation. In FQ vs non-FQ regimens, the overall rate of non-severe ADEs was 43.3% vs 6.1%. Tendinopathy, myalgia, arthralgia, and nausea were observed in correlation with administering FQs. This study overall describes a real-world view of the implications of FQ related adverse events on unplanned discontinuation when employed for prolonged durations in the management of staphylococcal PJIs.